Impact of clonal TP53 mutations with loss of heterozygosity on adjuvant chemotherapy and immunotherapy in gastric cancer.
1/5 보강
[BACKGROUND] This study aimed to reveal the effect of TP53 status on clinical outcomes and underlying mechanism in gastric cancer (GC) patients.
APA
Gu Y, Sun M, et al. (2024). Impact of clonal TP53 mutations with loss of heterozygosity on adjuvant chemotherapy and immunotherapy in gastric cancer.. British journal of cancer, 131(8), 1320-1327. https://doi.org/10.1038/s41416-024-02825-1
MLA
Gu Y, et al.. "Impact of clonal TP53 mutations with loss of heterozygosity on adjuvant chemotherapy and immunotherapy in gastric cancer.." British journal of cancer, vol. 131, no. 8, 2024, pp. 1320-1327.
PMID
39217196
Abstract
[BACKGROUND] This study aimed to reveal the effect of TP53 status on clinical outcomes and underlying mechanism in gastric cancer (GC) patients.
[METHODS] TP53 status was divided into three groups according to genome sequencing, namely clonal mutations with LOH (C-LOH), clonal diploid or subclonal mutations (CD-SC), and wild type (WT). The p53 protein activity was divided into over-expression (OE), Null and WT according to immunohistochemical staining. Four cohorts, including the TCGA, SMC, ZSHS and FUSCC cohort, were analyzed for association between TP53 mutation status and clinical outcomes and the underlying mechanism.
[RESULTS] In TCGA cohort, TP53 CD-SC were associated with superior overall survival compared to TP53 C-LOH cases. GC patients could benefit from ACT only in TP53 CD-SC/ p53 OE and TP53/ p53 WT subgroups, and TP53 C-LOH subgroup demonstrated the worst response to pembrolizumab among three subgroups. Genomic and immunophenotypic deconvolution revealed that TP53 C-LOH, CD-SC and WT differed for genomic and immune-related features.
[CONCLUSIONS] TP53 C-LOH GCs with genomic instability and immune evasion phenotype have poor clinical outcomes in patients treated with ACT or immunotherapy.
[METHODS] TP53 status was divided into three groups according to genome sequencing, namely clonal mutations with LOH (C-LOH), clonal diploid or subclonal mutations (CD-SC), and wild type (WT). The p53 protein activity was divided into over-expression (OE), Null and WT according to immunohistochemical staining. Four cohorts, including the TCGA, SMC, ZSHS and FUSCC cohort, were analyzed for association between TP53 mutation status and clinical outcomes and the underlying mechanism.
[RESULTS] In TCGA cohort, TP53 CD-SC were associated with superior overall survival compared to TP53 C-LOH cases. GC patients could benefit from ACT only in TP53 CD-SC/ p53 OE and TP53/ p53 WT subgroups, and TP53 C-LOH subgroup demonstrated the worst response to pembrolizumab among three subgroups. Genomic and immunophenotypic deconvolution revealed that TP53 C-LOH, CD-SC and WT differed for genomic and immune-related features.
[CONCLUSIONS] TP53 C-LOH GCs with genomic instability and immune evasion phenotype have poor clinical outcomes in patients treated with ACT or immunotherapy.
MeSH Terms
Humans; Stomach Neoplasms; Loss of Heterozygosity; Tumor Suppressor Protein p53; Chemotherapy, Adjuvant; Mutation; Female; Male; Immunotherapy; Middle Aged; Aged; Antibodies, Monoclonal, Humanized
같은 제1저자의 인용 많은 논문 (5)
- Sunitinib induces immunogenic cell death through eIF2α phosphorylation to potentiate immunotherapy in HCC.
- The gut-liver axis modulates intestinal immune homeostasis.
- Hexavalent chromium promotes malignant transformation via enhanced translation of SUV39H1.
- Systematic Review and Single-Arm Meta-Analysis of Bevacizumab Combined with Chemotherapy or Immunotherapy for Oncological Outcomes in Advanced/Recurrent Ovarian Clear Cell Carcinoma.
- Response to Letter to the Editor Regarding "Efficacy of Chinese Medicine on Postoperative Rehabilitation of Non-Small Cell Lung Cancer (NSCLC), a Randomized Controlled Study" in Integrative Cancer Therapies.